Talaris Therapeutics Stock Debt To Equity
TALSDelisted Stock | USD 2.98 0.10 3.25% |
Talaris Therapeutics fundamentals help investors to digest information that contributes to Talaris Therapeutics' financial success or failures. It also enables traders to predict the movement of Talaris Stock. The fundamental analysis module provides a way to measure Talaris Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Talaris Therapeutics stock.
Talaris |
Talaris Therapeutics Company Debt To Equity Analysis
Talaris Therapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Talaris Therapeutics Debt To Equity | 0.01 % |
Most of Talaris Therapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Talaris Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Talaris Therapeutics has a Debt To Equity of 0.015%. This is 99.97% lower than that of the Biotechnology sector and 99.92% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.97% higher than that of the company.
Talaris Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Talaris Therapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Talaris Therapeutics could also be used in its relative valuation, which is a method of valuing Talaris Therapeutics by comparing valuation metrics of similar companies.Talaris Therapeutics is currently under evaluation in debt to equity category among its peers.
Talaris Fundamentals
Return On Equity | -0.42 | |||
Return On Asset | -0.23 | |||
Current Valuation | (28.92 M) | |||
Shares Outstanding | 42.81 M | |||
Shares Owned By Insiders | 11.90 % | |||
Shares Owned By Institutions | 77.67 % | |||
Number Of Shares Shorted | 340.1 K | |||
Price To Book | 0.28 X | |||
EBITDA | (74.31 M) | |||
Net Income | (73.89 M) | |||
Cash And Equivalents | 207.11 M | |||
Cash Per Share | 4.97 X | |||
Total Debt | 2.88 M | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 28.92 X | |||
Book Value Per Share | 3.49 X | |||
Cash Flow From Operations | (60.86 M) | |||
Short Ratio | 4.01 X | |||
Earnings Per Share | (1.97) X | |||
Target Price | 20.0 | |||
Number Of Employees | 84 | |||
Beta | 2.18 | |||
Market Capitalization | 125.73 M | |||
Total Asset | 193.72 M | |||
Retained Earnings | (164.74 M) | |||
Working Capital | 174.15 M | |||
Z Score | 24.78 | |||
Net Asset | 193.72 M |
About Talaris Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Talaris Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Talaris Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Talaris Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Talaris Stock
If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |